Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms
NCT05206357Phase 1Active, not recruiting
- Sponsor
- Genmab
- Start
- Oct 2022
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab in mature B-cell neoplasm (MBCN), Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Genmab. Primary endpoints: Adverse Events at 3 years, Maximum Observed Concentration at 37 weeks and 1 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
mature B-cell neoplasm (MBCN)Burkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05206357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206357.